Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.8K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.8K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.1K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.9K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.9K
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.5K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.5K
Allergic Reactions02:06

Allergic Reactions

33.1K
Overview
33.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What's New in JEACP-Editor-in-Chief's Insights: Highlights from the latest issue.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Infantile Transient Smooth Muscle Contraction of the Skin in Two Sisters.

Pediatric dermatology·2026
Same author

The worldwide burden of skin diseases: Lessons from the Global Burden of Disease data.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

What's new in JEACP-Editor-in-chief's insights: Highlights from the latest issue.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

NEMO-NDAS: Case Report and Review of the Literature.

Pediatric dermatology·2026
Same author

Folliculotropic Mycosis Fungoides in a Teenager Treated With re-PUVA and Photodynamic Therapy.

International journal of dermatology·2026

Related Experiment Video

Updated: Mar 6, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K

Methylprednisolone aceponate for atopic dermatitis.

Antonio Torrelo1

  • 1Department of Dermatology, Hospital Infantil Niño Jesús, Madrid, Spain.

International Journal of Dermatology
|March 5, 2017
PubMed
Summary

Methylprednisolone aceponate (MPA), a potent topical corticosteroid, is safe and effective for treating atopic dermatitis (AD) in children. Its favorable risk-benefit profile supports its use in managing this chronic skin condition.

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Methylprednisolone aceponate (MPA) is a 4th generation topical corticosteroid (TCS) with a favorable risk-benefit ratio.
  • MPA is a potent, non-halogenated corticosteroid with enhanced intrinsic activity, classified as category III/IV.
  • Its properties make it suitable for managing chronic skin conditions like atopic dermatitis (AD).

Purpose of the Study:

  • To review the clinical efficacy, pharmacokinetics, and adverse effects of MPA.
  • To evaluate MPA's suitability for treating atopic dermatitis (AD), particularly in infants and children.

Main Methods:

  • Literature review of clinical studies on MPA.
  • Analysis of pharmacokinetic data and adverse effect profiles.

Main Results:

More Related Videos

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.7K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.6K

Related Experiment Videos

Last Updated: Mar 6, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.7K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.6K
  • Clinical studies confirm MPA's efficacy in infants and children with minimal local or systemic adverse effects.
  • MPA's pharmacokinetic profile and low adverse effect rate are ideal for treating extensive and chronic AD.
  • Effective management of AD requires comprehensive treatment of affected skin areas.

Conclusions:

  • Topical corticosteroids (TCS), including MPA, are effective in controlling AD.
  • Complete healing of eczema is crucial; emollients can be used post-treatment.
  • Physician training in early eczema recognition and adequate TCS application is vital for successful AD management.